• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconCOVID-19 vaccines

COVID-19 vaccines

Page 14 of 95
A sign advertising free COVID tests in New York City
HealthWhat is BA.4.6? The CDC is tracking a new COVID ‘variant of concern’ that’s overtaking earlier Omicron strains in at least 4 U.S. states
By Nicholas GordonAugust 4, 2022
Here come the Roarin’ 20s. Invest until it hurts
CommentaryHere come the Roarin’ 20s. Invest until it hurts
By John DiLulloAugust 2, 2022
Moderna COVID-19 vaccine
HealthU.S. reaches $1.74 billion deal with Moderna for its Omicron-specific vaccine
By Zeke Miller and The Associated PressJuly 29, 2022
Here’s what the pandemic really looks like in America’s medical deserts
CommentaryHere’s what the pandemic really looks like in America’s medical deserts
By Daniel GreenleafJuly 28, 2022
fauci-covid-booster-omicron
HealthFauci calls BA.5 a ‘moving target’ that may subside by the time Omicron boosters are ready. Scientists are pushing for a universal COVID vaccine instead
By Grady McGregorJuly 28, 2022
A global effort to stop the spread of COVID-19 in Africa is underway–and it starts with health care workers
CommentaryA global effort to stop the spread of COVID-19 in Africa is underway–and it starts with health care workers
By Adar PoonawallaJuly 27, 2022
Facebook considers relaxing COVID-19 misinformation policies
TechFacebook considers relaxing COVID-19 misinformation policies
By Chris MorrisJuly 26, 2022
pharmacy-covid-china-pill-antiviral
HealthChina just approved its first domestic anti-COVID pill, Azvudine, and is ready to produce 6.8 billion pills a year at half the price of Pfizer’s Paxlovid
By Grady McGregorJuly 26, 2022
Pfizer’s anti-COVID pill — used by Biden — is expected to rake in $23.2 billion, but confusion and weak demand could cause supply glut
HealthPfizer’s anti-COVID pill — used by Biden — is expected to rake in $23.2 billion, but confusion and weak demand could cause supply glut
By Chloe TaylorJuly 25, 2022
Bill Gates
HealthThe Bill & Melinda Gates Foundation partly funded an Omicron variant study with a surprising conclusion about boosters
By Christine MuiJuly 21, 2022
novavax-covid-vaccine-laboratory
HealthThe U.S.’s woefully low COVID vaccination rate makes it Novavax’s most appealing market yet
By Grady McGregorJuly 20, 2022
Ampoules containing the Corona vaccine Nuvaxovid from the manufacturer Novavax
HealthCDC endorses Novavax COVID shot for adults, adding to the number of vaccine options
By Lauran Neergaard and The Associated PressJuly 19, 2022
New viral threats are moving fast. Here’s how we can move faster
CommentaryNew viral threats are moving fast. Here’s how we can move faster
By Gavin ClohertyJuly 18, 2022
Novavax-lab-vaccine-covid
HealthA ‘breadth of protection’: Novavax’s newly approved COVID vaccine arms the U.S. with a new weapon against Omicron BA.5 subvariant
By Grady McGregorJuly 14, 2022
COVID finally got me. Will it come for you?
CommentaryCOVID finally got me. Will it come for you?
By Carolyn BarberJuly 12, 2022
1...
  • 12
  • 13
  • 14
  • 15
  • 16
...95
Most Popular
Politics
'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuzplaceholder alt text
By Fortune EditorsApril 11, 2026
Economy
'People are trying to be creative': Tariff-battered American companies are so cash-starved they are using refund claims as collateral for loansplaceholder alt text
By Fortune EditorsApril 12, 2026
Real Estate
A 93-year-old refused to sell her home to the Masters golf course that’s spent $280 million on expansion: ‘Money ain’t everything’placeholder alt text
By Fortune EditorsApril 12, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.